RecruitingPneumococcal Infection

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

Eligible age

0.2–1.3 yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.

Sponsor: Merck Sharp & Dohme LLC

You may qualify if…

✓ The main inclusion criteria include but are not limited to the following:
✓ Stage 1:
✓ Is previously vaccinated with 3 routine infant doses of Pneumococcal 20-valent conjugate vaccine (PCV20)
✓ Is 12 through 15 months of age
✓ Stage 2:
✓ \- Is approximately 2 months of age
✓ Both Stages:
✓ Was born at full term (gestational age greater than or equal to 37 weeks)

You may not qualify if…

✕ The main exclusion criteria include but are not limited to the following:
✕ Stage 1:
✕ \- Has received a PCV dose at 10 months of age and older
✕ Stage 2:
✕ Has received prior administration of any pneumococcal vaccine
✕ Both stages:
✕ Has a history of invasive pneumococcal disease (IPD)
✕ Has a known hypersensitivity to any component of V118C or PCV20 including diphtheria toxoid